摘要
目的:探讨重组人表皮生长因子衍生物滴眼液联合玻璃酸钠滴眼液治疗白内障术后干眼症的临床效果。方法:选取2021年3月至2023年3月潍坊眼科医院白内障术后干眼症患者100例,采用随机数表法分为生长因子-玻璃酸钠组和玻璃酸钠组,每组各50例。玻璃酸钠组采用玻璃酸钠滴眼液治疗,生长因子-玻璃酸钠组采用重组人表皮生长因子衍生物滴眼液联合玻璃酸钠滴眼液治疗,记录两组临床疗效以及眼部功能指标。结果:生长因子-玻璃酸钠组的治疗总有效率高达96.00%,而玻璃酸钠组仅为68.00%;同时,相较于玻璃酸钠组,生长因子-玻璃酸钠组的泪膜更为稳定,破裂时间更长,泪膜更厚,泪液分泌量也更大;此外,在角膜健康状况的评估上,生长因子-玻璃酸钠组的角膜荧光素染色评分和眼表疾病指数评分都低于玻璃酸钠组;相比较差异均有统计学意义(P<0.05)。两组不良反应情况差异无统计学意义(P>0.05)。结论:重组人表皮生长因子衍生物滴眼液联合玻璃酸钠滴眼液治疗白内障术后干眼症效果好。这一联合治疗方案不仅提高了治疗有效率,还改善了泪膜的稳定性和角膜的健康状况,为白内障术后干眼症患者带来了福音。
Objective:To investigate the clinical efficacy of recombinant human epidermal growth factor derivative eye drops combined with sodium hyaluronate eye drops in the treatment of dry eye syndrome after cataract surgery.Methods:100 patients with dry eye syndrome after cataract surgery at Weifang Eye Hospital were selected from March 2021 to March 2023,and were divided into observation group and control group by random number table method,with 50 patients in each group.The control group was treated with sodium hyaluronate eye drops,and the observation group was treated with recombinant human epidermal growth factor derivative eye drops combined with sodium hyaluronate eye drops.The clinical efficacy as well as ocular function indexes of the two groups were recorded.Results:The treatment efficiency of the observation group was as high as 96.00%,while that of the control group was only 68.00%.Meanwhile,compared to the control group,the observation group had a more stable tear film,longer rupture time,thicker tear film,and greater tear secretion.In addition,the corneal fluorescein staining score and the ocular surface disease index score of the observation group were lower than those of the control group in the assessment of corneal health.These differences were statistically significant(P<0.05).However,there was no significant difference in the adverse reaction profile between the two groups(P>0.05).Conclusion:The combination of recombinant human epidermal growth factor derivative eye drops and sodium hyaluronate eye drops is effective in treating dry eye syndrome after cataract surgery.This combination therapy not only improves the treatment efficacy,but also enhances the stability of the tear film and the health of the cornea,which brings good news for patients with dry eye syndrome after cataract surgery.
作者
徐奇
XU Qi(Weifang Eye Hospital,Weifang 261000,China)
出处
《延边大学医学学报》
CAS
2024年第4期425-427,共3页
Journal of Medical Science Yanbian University
关键词
重组人表皮生长因子衍生物滴眼液
玻璃酸钠滴眼液
白内障
干眼症
Recombinant human epidermal growth factor derivative eye drops
Sodium hyaluronate eye drops
Cataract
Dry eye syndrome
作者简介
徐奇(1993-),男,汉族,籍贯:山东潍坊,本科,主治医师,研究方向:白内障、干眼症。
